NeoX Biotech

About NeoX Biotech

NeoX Biotech, established in 2018 by Dr. Chen Li and Dr. Michael Xiao, is a biotechnology firm leveraging a synergistic approach of artificial intelligence, biophysics, and high-throughput experimentation to develop novel therapeutics. Dr. Li, serving as Chairman and CEO, brings a wealth of experience from his time at Johnson & Johnson, where he led R&D and venture investment in the Asia Pacific region. Dr. Xiao, the co-founder and COO, contributes his extensive background in computational chemistry and drug design from his tenure at Schrödinger. This blend of pharmaceutical R&D and computational expertise forms the foundation of the company's strategy.

The company's core focus is on unraveling the complexities of dynamic protein-protein interactions (PPIs) to create differentiated drugs for areas with significant unmet medical needs. Its proprietary platform integrates AI-driven computation with laboratory experiments to accelerate the discovery process for large-molecule and multi-specific drugs. Headquartered in Beijing, NeoX Biotech maintains a global presence with research teams in Shanghai and the US, strategically positioning itself within key life science hubs.

NeoX Biotech's business model revolves around advancing its internal pipeline and forging strategic co-development partnerships. The company generates value by discovering and developing drug candidates to a preclinical or early clinical stage, at which point it seeks out-licensing opportunities with larger pharmaceutical partners. The pipeline is concentrated on two primary modalities: neoBiologics, which includes antibody, nanobody, and protein drugs, and neoDegrader, which focuses on Targeted Protein Degradation (TPD) agents like PROTACs and molecular glues. Several of its antibody-based drugs and PROTAC degraders have advanced to the candidate-selection or IND-enabling stages, signaling a maturing portfolio ready for strategic alliances.

Financially, NeoX Biotech has demonstrated the ability to attract significant capital, securing a $100 million Series B financing round in 2021, co-led by prominent investors including CPF and CSC GRS, with participation from others like Vision Plus Capital and Sequoia China. This funding is directed towards advancing its preclinical programs, expanding its drug discovery platform, and growing its research teams. The firm operates in the highly competitive biopharmaceutical market, targeting complex diseases by designing drugs that can modulate previously hard-to-target protein interactions.